Results 161 to 170 of about 281,052 (341)
The release of COL6A3 by fibroblasts is sensed by the CD44 receptor on melanocytes, activating glutathione (GSH) metabolism and increasing melanocyte survival during skin organoid culture. SEMA3C released by bulge cells binds to the NRP1 receptor on melanocytes, regulating microtubule stability and promoting melanocyte recruitment and function during ...
Tingting Li+17 more
wiley +1 more source
M, Díaz, M A, Campanero
openaire +2 more sources
KRAS mutations dynamically remodel the tumor microenvironment (TME), fostering immunosuppression, metabolic symbiosis, and stromal plasticity. This review dissects how oncogenic KRAS variants sculpt TME networks and explores actionable vulnerabilities. Emerging strategies combining KRAS inhibitors and TME‐editing approaches offer potential to dismantle
Jiayao Ma+9 more
wiley +1 more source
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group [PDF]
Jan P. van Meerbeeck+11 more
openalex +1 more source
A CDSP NPs theranostic platform assembled from CDs and paclitaxel prodrugs is developed. CDSP NPs have long‐lasting NIR afterglow, penetrate deep tissues, and offer a high signal‐to‐noise ratio, enabling NIR afterglow imaging‐guided precise breast cancer removal to prevent recurrence.
Zixuan Li+4 more
wiley +1 more source
Background and objective Second-line chemotherapy with taxanes for the patients with non-small cell lung cancer (NSCLC), who had disease recurrence or failure in previously treated with platinum-based chemotherapy, has been shown to be effective. Besides
Tianqing CHU+4 more
doaj
In ovarian tumors with high CMTM4 expression, exosomes transfer CMTM4 to macrophages, upregulating ICAM1 and promoting M2 polarization via p65 nuclear translocation. This suppresses immunity by increasing PD‐1 and Tregs while reducing CD8+ T cells.
Bo Yin+12 more
wiley +1 more source
Background Paclitaxel, a tubulin-binding agent, is a Food and Drug Administration-approved first-line drug for the treatment of non-small cell lung cancer (NSCLC), for both squamous and non-squamous cell lung carcinoma, with paclitaxel/carboplatin ...
Yanyan Lu+3 more
doaj +1 more source
A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium [PDF]
Christopher J. Sweeney+7 more
openalex +1 more source
ICAM1 antibody‐bound ICG triggers tumor‐specific, caspase‐1‐independent pyroptosis via CTSS‐mediated GSDMD cleavage, activates antitumor immunity, and synergizes with anti–PD‐1 therapy, offering a non‐apoptotic strategy to overcome resistance in cancer treatment.
Fan Chen+17 more
wiley +1 more source